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Patients with adenocarcinoma and non-smoking had better 
survival in chemotherapy of gemcitabine plus oral UFT for 
advanced non-small-cell-lung cancer previously treated with 
platinum
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Background: An open-label single-arm clinical study was conducted 
to evaluate the efﬁcacy and toxicity of combination of gemcitabine and 
UFT in patients with advanced non-small-cell-lung cancer (NSCLC) 
after failure of previous platinum-containing regimens. 
Methods: Patients with advanced NSCLC received an oral administra-
tion of UFT (tegafur 400 mg/m2/day) from days 1 to 14 and intravenous 
injection of gemcitabine 900 mg/m2 on days 8 and 15. This treatment 
was repeated every 3 or 4 weeks. 
Results: A total of 40 patients were enrolled into this study. Eleven 
patients (28%; 95%CI: 14-41%) achieved a partial response. The 
median progression-free survival, median overall survival and 1-year 
survival rate were 121 days, 383 days and 50%, respectively. The most 
common grade 3-4 toxicity was neutropenia (38%) while the frequency 
of grade 3-4 non-hematologic toxicities remained at less than 5%. This 
combination chemotherapy demonstrated a promising effectiveness 
and acceptable toxicity proﬁle for platinum-resistant NSCLC patients. 
A multivariate Cox regression analysis exhibited that adenocarcinoma 
and non-smoking habit as well as good performance status predict bet-
ter survival outcome. 
Conclusions: These factors could potentially bring in serious im-
pact into results of clinical studies for second-line chemotherapy of 
advanced NSCLC. 
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A bi-weekly administration of gemcitabine and docetaxel in 
patients with non-small cell lung cancer
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Background: Combination of gemcitabine and docetaxel (GEM/DOC) 
has shown a favorable activity with its response rate of 34-37.5%, simi-
lar to that of cisplatin and docetaxel in chemotherapy-naïve patients 
with stage IIIb or IV non-small cell lung cancer (NSCLC). However, 
neutropenia and pulmonary toxicities were related to the combination 
chemotherapy. Especially relatively high rate of pulmonary toxicities 
have been identiﬁed in monthly or weekly administration setting of 
both combination.
Purpose: We evaluated the feasibility and efﬁcacy of biweekly GEM/
DOC chemotherapy in patients with NSCLC.
Patients and Methods: Forty-four patients with post-operative recur-
rences and eighteen patients with unresectable advanced non-small cell 
lung cancer were enrolled in this study.
Those patients received 1000mg/m2 of GEM and 30mg/m2 of DOC 
bi-weekly, q=2 weeks. Response rate, toxicities, and completion rate 
are evaluated after 4 cycles. Those patients were basically treated on 
outpatient basis.
Results: A total of 62 patiets were treated with combination of GEM/
DOC. 
Patients characteristics were as follows; recurrent/unresectable: 44/18; 
male/female: 38/24; median age: 66.1 (range 32-80); perfomance status 
0/1/2: 41/19/2; adeno/squamous/large: 45/15/2; chemo naïve/previ-
ously treated: 24/38.
A response rate was 20.7%(CR 3, PR 9, SD 34, PD 12, and NE 4). 
Response rates by tumor pathological type were 25% (11/44) with 
adenocarcinoma and 8.3% (1/12) with squamous cell carcinoma. Over 
grade 3 leucopenia was occurred in 17.7% (11/62), neutropenia in 
32.3% (20/62), skin toxicities in 3.2% (2/62), and pulmonary toxici-
ties in 3.2% (2/62). Treatment completion rate was 93.5%(58/62). The 
reasons of treatment discontinuation were pneumonia, skin rush, and 
angiodynia.
Conclusion: GEM/ DOC regimen is a feasible and efﬁcacious regimen 
against advanced and/or recurrent NSCLC. Biweekly administration of 
GEM/DOC may decrease hematological toxicities and be well-toler-
ated regimen. In addition, the rate of pulmonary toxicities in biweekly 
GEM/DOC may be less compared with other scheduled combination.
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Prospective phase II trial of a combination of gemcitabine, 
cisplatin and UFT as first-line treatment in patients with advanced, 
unresectable, non-small cell lung carcinoma
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Backgroud: Most patients with advanced non-small cell lung cancer 
(NSCLC) receive either single agents or doublet chemotherapy. For 
non-elderly pts in good performance status, platinum-based double 
combinations represent the standard treatment. Meta-analysis have 
showed combination chemotherapy consisting of cisplatin plus new 
agent yielded a substantial survival advantage compared with carbo-
platin plus new agent in patients with advanced NSCLC. And oral UFT 
had the survival advantage in adjuvant setting. Gemcitabine may be 
more effective in form of ﬁxed dose rate infusion (FDRI, 10 mg/kg/
min) than conventional infusion schedule. Therefore we performed a 
phase II study using the combination of gemcitabine, cisplatin and UFT 
as a ﬁrst line therapy in patients with advanced NSCLC.
Methods: Eligible patients had histologically or cytologically con-
ﬁrmed stage IIIB or IV NSCLC with good performance status and were 
chemotherapy-naive. This study was two-stage design and planned 
number of patients was forty-seven. Gemcitabine (1,250mg/m2, 10mg/
kg/min on days 1 and 8) and cisplatin (75mg/§⁄ on day 1) were injected 
intravenously and UFT (400mg/day) was administered orally on day 1-
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14. Treatment repeated every 3 weeks until progression up to maximum 
six cycles. Primary end point was overall response rate and secondary 
end points were overall survival, time to progression and toxicity.
Results: Thirty seven patients with advanced NSCLC were enrolled. 
The median age of the patients was 60 years (range: 44 to 72). The per-
formance status (WHO) was 0 in 4, 1 in 30 and 2 in 3 patients. Twenty 
three patients completed six cycles. Complete response was achieved in 
1 (3%) patient, partial response in 22 (59%) patients, stable disease in 9 
(24%) patients. Overall response rate was 62% on intent to treat basis. 
Among patients who response evaluation was possible (33 patients), re-
sponse rate was 70%. The median survival time was 14.5 months (95% 
CI 6.9, 22.3) and the 1 year survival was 35% and then median time to 
progression was 3.4 months(95% CI 3, 3.9). Toxicities were moder-
ate and mostly hematological adverse events. Grade 3/4 neutropenia 
occurred in 37%, 5 patients with febrile neutropenia. Grade 3/4 anemia 
and thrombocypenia was occurred in 37% and 5%. Nonhematologic 
toxicities were mild. 
Conclusion: The combination therapy consisted of gemcitabine, cispla-
tin and UFT is active and well tolerable ﬁrst line regimen for NSCLC 
patients. 
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Phase II trial of adjuvant chemotherapy with bi-weekly 
carboplatin plus paclitaxel in patients with completely resected 
non-small cell lung cancer
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Background: Cisplatin-based adjuvant chemotherapy improves 
survival in completely resected NSCLC patients, in recent phase III 
trials, such as IALT, JBR10 and ANITA. This phase II trial assessed the 
efﬁcacy and safety proﬁles of bi-weekly schedule of carboplatin and 
paclitaxel as adjuvant chemotherapy.
Methods: Patients registered from July 2001 to October 2003. Eligibil-
ity criteria included: completely resected NSCLC (Stage IB, IIA/B, 
IIIA/B (pm1)), PS 0-1, age less than 80, no prior chemotherapy/ra-
diotherapy, adequate hematological, liver, renal functions, written 
informed consent. The patients received chemotherapy with paclitaxel 
90mg/m2 and carboplatin AUC3 every 2 weeks x6, within 8 weeks after 
surgery. As a short premedication, 8 mg of dexamethasone, 5mg of d-
chlorpheniramine maleate and 50mg of ranitidine were administered in-
travenously 30 minutes, before the patients receive paclitaxel. Primary 
endpoints were disease-free survival and adverse events. Secondary 
endpoint was compliance.
Results: Seventy-two patients were enrolled in this study. Of these, 5 
patients were considered ineligible; 4 patients were out of criteria and 1 
patient did not receive chemotherapy. Then, 67 patients were evaluable 
for disease-free survival and adverse events. Fifty patients (74.6%) 
completed all cycles of therapy, and the average number of cycles 
administered was 5.1. Enrolled patients consisted of 50 males and 17 
females, with median age 64 (range; 33-79). They included 41 adeno-
carcinomas, 21 squamous cell carcinomas, 3 large cell carcinoma and 2 
others. Twenty-four patients were in Stage IB, 16 in II, 21 in IIIA, 6 in 
IIIB. The hematologic adverse event was mild and consisted mostly of 
neutropenia, in 7 patients for grade 3, and 2 for grade 4. These events 
in grade 3/4 occurred 19% in less than 60 y/o, 8% in 60-69 y/o, and 
15% in more than 70 y/o. The non-hematologic adverse events were 
observed in 6 patients for grade 3, such as general fatigue, appetite loss, 
constipation, diarrhea, colitis, peripheral nerve disorder, arthralgia. 
The median follow-up period was 1102 days (141-1674 days). The 
frequency of recurrent-disease was 26.9% (IB 16%, IIA 0%, IIB 23%, 
IIIA 40%, and IIIB 50%). The 4-year disease-free survival and overall 
survival rates of 67 patients were 72.4% and 77.9% respectively. The 
4-year disease-free survival of patients with IB-II was 82.1% and that 
of patients with III-IV were 57.8%. The 4-year overall survival rate in 
stage IB-II and III-IV were 85.4% and 67.7%, respectively.
Conclusions: Bi-weekly schedule of carboplatin and paclitaxel as ad-
juvant chemotherapy was well tolerated in completely resected NSCLC 
patients, also in elderly patients. The results of our trial suggest favor-
able outcome in both disease-free and overall survivals, therefore, it 
seem to be a candidate arm of further trial.
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Randomized phase II study of carboplatin and paclitaxel (CP) 
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Background: Although doublet chemotherapy is a standard treat-
ment regimen for PS 0-1 patients with advanced NSCLC, the optimal 
chemotherapy for previously untreated PS 2 patients with advanced 
NSCLC still remains to be established. We conducted a randomized 
phase II study to compare the efﬁcacy and safety of a platinum-doublet 
regimen (CP) versus a non-platinum doublet regimen (GV) in PS 2 
patients with advanced NSCLC. 
Patients and Methods: Chemotherapy-naive patients with stage IIIB 
(malignant effusion) and IV NSCLC were eligible for this study. All pa-
tients were required ECOG PS 2. The patients were randomly assigned 
to carboplatin area under the curve of 6 plus paclitaxel 200 mg/m2 on 
day 1 every 3 weeks (the CP arm) or gemcitabine 1000 mg/m2 plus 
vinorelbine 25 mg/m2 on days 1 and 8 every 3 weeks (the GV arm). 
The primary endpoint was 1-year survival rate while the secondary 
endpoints were response rate, time to progression, toxicity, and quality 
of life (QOL). The sample size was 41 assessable patients in each arm.
